SELLAS Life Sciences (SLS) Free Cash Flow (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Free Cash Flow for 17 consecutive years, with -$8.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 2.98% year-over-year to -$8.8 million; the TTM figure through Mar 2026 stood at -$28.1 million (up 16.56% YoY), while the FY2025 annual figure was -$28.4 million, up 19.78% from the prior year.
• Free Cash Flow fell to -$8.8 million in Q1 2026 per SLS's latest filing, from -$4.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$4.8 million in Q4 2023 and bottomed at -$12.1 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$7.5 million across 5 years, with a median of -$7.2 million in 2024.
• Annual changes were most pronounced in 2023 — Free Cash Flow plunged 69.61% — and 2025, when it soared 31.05%.
• SELLAS Life Sciences' Free Cash Flow stood at -$5.2 million in 2022, then climbed by 6.35% to -$4.8 million in 2023, then sank by 48.25% to -$7.2 million in 2024, then jumped by 31.05% to -$4.9 million in 2025, then tumbled by 78.43% to -$8.8 million in 2026.
• Business Quant data shows SLS's Free Cash Flow at -$8.8 million in Q1 2026, -$4.9 million in Q4 2025, and -$7.1 million in Q3 2025.